Biocon to Merge Biologics Unit in $5.5 Billion Deal

Biocon to merge biologics unit in $5.5 billion deal

India News: Biocon has announced a bold step in the biopharmaceutical landscape by merging its biosimilars division, Biocon Biologics, into the parent organizatio

Biocon to Fully Integrate Biocon Biologics

Bengaluru, Karnataka, India: December 06, 2025: Biocon Limited (BSE code: 532523, NSE: BIOCON),  an innovation-led global biopharmaceuticals company, today announced a strategic corporate action to fully integrate Biocon Biologics Limited (BBL) as a wholly owned subsidiary into Biocon Limited,  subject to applicable approvals. Biocon Limited is constituting a Governance Council chaired by Kiran  Mazumdar-Shaw and […] The post Biocon Limited to I…

Biocon to Fully Integrate Biocon Biologics in $5.5 Billion Share-Swap Deal

Indian biopharmaceutical major Biocon announced on Saturday that it will fully integrate its biosimilar arm, Biocon Biologics, making it a wholly owned subsidiary. The company will acquire remaining stakes from Serum Institute Life Sciences, Tata Capital Growth Fund II, and Activ Pine LLP through a share swap of 70.28 Biocon shares for every 100 Biocon Biologics shares, valuing the biosimilars unit at $5.5 billion. The decision comes after evalu…

Biocon fully integrates Biocon Biologics in $5.5 billion deal - Regional Media News

By Rishabh Jaiswal and Rishika Sadam BENGALURU, Dec 6 (Reuters) - Indian biopharmaceutical company Biocon said on Saturday it would fully integrate its biosimilar unit Biocon Biologics as a wholly owned subsidiary, consolidating Biocon's biosimilars and generics businesses under one roof. Biocon said it will acquire the remaining stakes in Biocon Biologics from Serum Institute Life Sciences, Tata Capital Growth Fund II and Activ Pine LLP through…